Please provide your email address to receive an email when new articles are posted on . Dabigatran is an oral anticoagulant - a synthetic thrombin inhibitor – that is approved in the United States for ...

Dabigatran has been associated with an increase in acute coronary events when compared with warfarin in several randomized trials, and now in a meta-analysis by Uchino and Hernandez. We critically ...

Ascend Laboratories, maker of generic dabigatran etexilate, is recalling 10 manufacturing lots of the oral anticoagulant because of an unacceptably high level of a possible carcinogen, according to a ...

SILVER SPRING, Maryland — The US FDA is following in the footsteps of the European Medicines Agency (EMA) in warning that the anticoagulant dabigatran (Pradaxa, Boehringer Ingelheim) should not be ...

In two trials exploring potential new indications, dabigatran (Pradaxa; Boehringer Ingelheim) failed to show significant advantages over standard treatments for embolic stroke of undetermined source ...

The Appraisal Committee reviewed the data available on the clinical and cost effectiveness of dabigatran, having considered evidence on the nature of atrial fibrillation and the value placed on the ...

The new findings, presented Sunday at the American Society of Hematology (ASH) 2009 Meeting and published online in the New England Journal of Medicine, come hard on the heels of the RE-LY results, ...

The availability of dabigatran 110 mg in the US may be a favorable therapeutic option for patients at high risk of bleeding, who may be willing to accept a higher probability of stroke for a reduced ...

In patients with atrial fibrillation (AF), treatment with the direct thrombin inhibitor dabigatran etexilate is safe and effective at twice-daily doses of either 150 mg or 110 mg, report the ...

The summary of product characteristics states that the recommended daily dose of dabigatran is 300 mg taken as one 150-mg capsule twice daily. Therapy is continued long term. For patients aged 75 to ...